# Amicus Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amicus-therapeutics

- Industry: Biotechnology
- Headquarters: US
- Website: www.amicusrx.com
- Total disclosed funding: $123M
- Latest round: Series D (Sep 13, 2006)
- Investors on record: 9

## About

Based in New Jersey, US, and founded in 2002 by John F. Crowley, Amicus Therapeutics, Inc. operates as a biotechnology company providing medicine for rare metabolic diseases, including a rare disease gene therapy. In January 2010, Alzheimer's Drug Discovery Foundation invested USD 0.21 million in Amicus Therapeutics, Inc. 

Amicus Therapeutics, Inc. developed a product known as galafold, that allows healthcare professionals to treat and diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data. The company offers pombiliti + opfolda for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing. In addition, the firm provides program known as amicus assist, that provides personalized support to individuals who have been prescribed an Amicus medication.

## Funding rounds

- Series D, Sep 13, 2006, $35M — CHL Medical Partners, Frazier Healthcare Partners, New Enterprise Associates, Prospect Venture Partners, Quaker Partners Management, Canaan Partners, Radius Ventures, Palo Alto Investors, Sculptor
- Series C, Sep 8, 2005, $55M — CHL Medical Partners, Frazier Healthcare Partners, New Enterprise Associates, Prospect Venture Partners, Quaker Partners Management, Canaan Partners, Radius Ventures, Palo Alto Investors
- Series B, May 12, 2004, $31M — CHL Medical Partners, Frazier Healthcare Partners, New Enterprise Associates, Prospect Venture Partners, Canaan Partners, Radius Ventures
- Series A, Jul 25, 2002, $2M — CHL Medical Partners

## Investors

- CHL Medical Partners (https://capitalatlas.ai/funds/chl-medical-partners) — Series A, Series B, Series C, Series D
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series B, Series C, Series D
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series B, Series C, Series D
- Prospect Venture Partners (https://capitalatlas.ai/funds/prospect-venture-partners) — Series B, Series C, Series D
- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series B, Series C, Series D
- Radius Ventures (https://capitalatlas.ai/funds/radius-ventures) — Series B, Series C, Series D
- Quaker Partners Management (https://capitalatlas.ai/funds/quaker-partners-management) — Series C, Series D
- Palo Alto Investors (https://capitalatlas.ai/funds/palo-alto-investors) — Series C, Series D
- Sculptor (https://capitalatlas.ai/funds/sculptor) — Series D